The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Date Broker Recommendation Old Target New Target Rating Type
17-Apr-24 Canaccord Genuity Speculative Buy - 160.00 Reiteration
First of all thank you Tamovv and Stupmy for your input, I know we are down due to Divi, but if the deal does not materialize, will that hit the SP or are we valued as per the results ?
Https://uk.advfn.com/stock-market/london/parkmead-PMG/share-news/Parkmead-Group-The-PLC-Interim-Results-for-Six-Months-Ended-31-Dec-2023/93564171
· This is the first time that the Fynn Beauly accumulation has been licensed to a single partner group, creating an exciting opportunity for Parkmead (50% stake) and its partner, Orcadian Energy (50%) to advance the development of this substantial resource
Being an AIM share, Surprised no leaked news....
So were all those buy backs worth it?
Thanks to ohisay on advfn...
https://www.youtube.com/watch?v=dXs-1flsjtY
Worth watching for those at home....
https://whatson.parliament.uk/
https://whatson.parliament.uk/event/cal46430
WASHINGTON (AP) — US employers added a surprisingly strong 216,000 jobs in December in a sign of continued economic strength.
Jefferies raises Harbour Energy price target to 360 (340) pence - 'buy'